Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of TY-9591 Tablets in Patients With EGFR-Mutated Non-small Cell Lung Cancer With Brain Metastases

NCT05948813 is registered in ClinicalTrials.gov with TYK Medicines, Inc as lead sponsor.

NCT NCT05948813
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05948813 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of TY-9591 Tablets in Patients With EGFR-Mutated Non-small Cell Lung Cancer With Brain Metastases
Lead sponsor
TYK Medicines, Inc
Phase
Phase 2
Overall status
Recruiting
Start date
August 17, 2023
Completion date
March 30, 2030
Enrollment
420 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, egfr activating mutation, nsclc